Open AccessAcute toxicity and patient‐reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer
Author(s) -
Iizumi Takashi,
Ishikawa Hitoshi,
Sekino Yuta,
Tanaka Keiichi,
Takizawa Daichi,
Makishima Hirokazu,
Numajiri Haruko,
Mizumoto Masashi,
Nakai Kei,
Okumura Toshiyuki,
Sakurai Hideyuki
Publication year - 2022
Publication title -
journal of medical radiation sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.484
H-Index - 18
eISSN - 2051-3909
pISSN - 2051-3895
DOI - 10.1002/jmrs.551
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , adverse effect , genitourinary system , acute toxicity , prostate , toxicity , international prostate symptom score , proton therapy , oncology , dose fractionation , urology , cancer , radiation therapy , lower urinary tract symptoms
Abstract Introduction To confirm the feasibility of hypofractionated proton beam therapy (PBT), we compared the acute adverse event rates and International Prostate Symptom Score (IPSS) in prostate cancer patients treated with hypofractionated versus conventionally fractionated (2.0 Gy relative biological effectiveness (RBE)/fraction) PBT. Methods We reviewed 289 patients with prostate cancer, of whom 73, 100, and 116 patients were treated with 2.0, 2.5, and 3.0 Gy (RBE)/fraction, respectively. The endpoints were acute genitourinary and gastrointestinal toxicities and the IPSS, evaluated up to 6 months after PBT initiation. Results No significant differences were found in acute toxicity rates or the IPSS among the fractionation schedules. Diabetes mellitus, age, and androgen deprivation therapy were not identified as factors associated with the IPSS. Conclusion There were no significant differences in adverse events or quality of life among the three fractionation schedules early after PBT.